Literature DB >> 9778226

Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.

A M van Gestel1, C J Haagsma, P L van Riel.   

Abstract

OBJECTIVE: To study the validity of response criteria for rheumatoid arthritis (RA) that included 28-joint counts instead of more comprehensive joint counts.
METHODS: In a double-blind, placebo-controlled trial of 105 patients treated with methotrexate, sulfasalazine, or both, response was evaluated at week 52. Both European League Against Rheumatism and American College of Rheumatology definitions of response, with comprehensive as well as simplified joint counts, were calculated. We studied the differences between the criteria with and without simplified joint counts, the discriminating capacity between treatment groups, and the association with change in functional capacity and joint damage.
RESULTS: Response criteria that included 28-joint counts classified patients' responses more conservatively. No differences between treatment groups were found with either set of response criteria. The association with change in functional capacity was significant in all cases. All response criteria were significantly associated with radiographic progression of RA.
CONCLUSION: Improvement criteria that include 28-joint counts are as valid as the original improvement criteria that included more comprehensive joint counts.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9778226     DOI: 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  262 in total

1.  A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine.

Authors:  Jessica Wojciechowski; Michael D Wiese; Susanna M Proudman; David J R Foster; Richard N Upton
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

Review 2.  My treatment approach to rheumatoid arthritis.

Authors:  John M Davis; Eric L Matteson
Journal:  Mayo Clin Proc       Date:  2012-07       Impact factor: 7.616

3.  Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort.

Authors:  Clio P Mavragani; Dan T La; William Stohl; Mary K Crow
Journal:  Arthritis Rheum       Date:  2010-02

4.  Is DAS28-CRP with three and four variables interchangeable in individual patients selected for biological treatment in daily clinical practice?

Authors:  Ole Rintek Madsen
Journal:  Clin Rheumatol       Date:  2011-09-29       Impact factor: 2.980

5.  Pulmonary involvement in early rheumatoid arthritis patients.

Authors:  Hisham M Habib; Ashraf A Eisa; Waleed R Arafat; Mohamed A Marie
Journal:  Clin Rheumatol       Date:  2010-05-26       Impact factor: 2.980

6.  Quality of life in Indian patients with rheumatoid arthritis.

Authors:  Gurdesh S Bedi; Nikhil Gupta; Rohini Handa; Hemraj Pal; R M Pandey
Journal:  Qual Life Res       Date:  2005-10       Impact factor: 4.147

7.  Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib.

Authors:  Diana S Novikova; Helen V Udachkina; Eugenia I Markelova; Irina G Kirillova; Anna S Misiyuk; Natalia V Demidova; Tatiana V Popkova
Journal:  Rheumatol Int       Date:  2019-05-03       Impact factor: 2.631

8.  Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort.

Authors:  Veena K Ranganath; Jeonglim Yoon; Dinesh Khanna; Grace S Park; Daniel E Furst; David A Elashoff; Damini Jawaheer; John T Sharp; Richard H Gold; Edward C Keystone; Harold E Paulus
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

9.  Polymorphism of the beta3-adrenergic receptor and lipid profile in patients with rheumatoid arthritis and systemic lupus erythematosus treated with chloroquine.

Authors:  J F Muñoz-Valle; M Vázquez-Del Mercado; S Ruiz-Quezada; E Oregón-Romero; R E Navarro-Hernández; J Ramírez-Barragán; G Martínez-Bonilla; G Bernard-Medina; B E Bastidas-Ramírez; B Ruiz-Madrigal; A Panduro
Journal:  Rheumatol Int       Date:  2003-03-12       Impact factor: 2.631

10.  Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis.

Authors:  Joerg Christoph Henes; Joerg Schedel; Lothar Kanz; Ina Koetter
Journal:  Rheumatol Int       Date:  2009-12-12       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.